Sourcejournal articleno stored text

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Paul M Ridker, Brendan M. Everett, Tom Thuren, Jean G. MacFadyen, William H. Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D. Anker, John J.P. Kastelein, Jan H. Cornel, Prem Pais, Daniel Pella, Jacques Genest, Renata Cifkova, Alberto Lorenzatti, Tamas Forster, Zhanna Kobalava, Luminita Vida-Simiti, Marcus Flather, Hiroaki Shimokawa, Hisao Ogawa, Mikael Dellborg, Paulo R.F. Rossi, Roland P.T. Troquay, Peter Libby, Robert J. GlynnNew England Journal of MedicinePublished Sep 21, 2017doi 10.1056/nejmoa1707914 Original︎ ↗Archived copy

Claims2

ExaminationsNone

TextNot stored

VersionsOne known

CopiesNone recorded

CorrectionsNone recorded

Facts checked Nov 9, 2026

ReachNo copies recorded

StructureIn 2 claims' maps0 sources downstream across 2 claims

EvidenceNot yet read

ReviewsNot reviewed

Examinations

None recorded. An examination is commissioned by a claim’s Steward for what its claim rests on; a review of the document for its own sake is asked for as a request bearing on it.

Text

No stored copy. Only the passages claims quote are recorded.

As quoted

Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering.

At least some anti-inflammatory therapies reduce cardiovascular events independently of lipid loweringSupported

Not yet read by this claim’s Steward.

As quoted

Canakinumab significantly reduced high-sensitivity C-reactive protein levels from baseline, as compared with placebo, without reducing the LDL cholesterol level, and the 150-mg dose resulted in a significantly lower incidence of recurrent cardiovascular events than placebo.

In the CANTOS trial, canakinumab reduced recurrent cardiovascular events without lowering LDL cholesterolVerified

Not yet read by this claim’s Steward.

Lineage across 2 claims

Draws on · none recorded

This source

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

in 2 claims' maps

Drawn on by · none recorded

Record

Kind: journal article
Authors: Paul M Ridker, Brendan M. Everett, Tom Thuren, Jean G. MacFadyen, William H. Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D. Anker, John J.P. Kastelein, Jan H. Cornel, Prem Pais, Daniel Pella, Jacques Genest, Renata Cifkova, Alberto Lorenzatti, Tamas Forster, Zhanna Kobalava, Luminita Vida-Simiti, Marcus Flather, Hiroaki Shimokawa, Hisao Ogawa, Mikael Dellborg, Paulo R.F. Rossi, Roland P.T. Troquay, Peter Libby, Robert J. Glynn
Publisher: New England Journal of Medicine
Published: Sep 21, 2017
DOI: 10.1056/nejmoa1707914
Link: https://www.nejm.org/doi/full/10.1056/NEJMoa1707914
Archived copy: https://web.archive.org/web/20260430112534/https://www.nejm.org/doi/full/10.1056/NEJMoa1707914
Stored text: None; quoted passages only
Claims extracted: Not recorded
Versions: One known
Copies: None recorded
Corrections: None recorded
Facts checked: Nov 9, 2026

History 3

Nov 9, 2026FactsFacts fetcher · Facts looked up
Nov 4, 2026Correction watchCorrection watcher · Watched by DOI; no notice found
Aug 7, 2026Entered the graphEntered the graph; no copy stored